Stock Analysis of Dermata Therapeutics Inc (DRMA) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code DRMA
Close 3.83
Change 0.215 / 5.94 %
Volume 43727.00
Vol Change 33606.00 / 332.04 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bearish
Growth Index Mild Growth
Value Index Low Value Stock
Profitability Index Poor Profitability Stock
Stability Index Excellent Stability


Fundamental View of Dermata Therapeutics Inc
PE (TTM)

-0.121

Very Poor
Price / Book

0.161

Excellent
Price / Sales

0

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

1702.95 K

Enterprise Value

-7436.43 M

ROA (TTM)

-112.87

Very Poor
ROE (TTM)

-132.91

Very Poor
Net Margin (TTM)

0

Poor
Revenue

%

0
Net Profit

23.73 %

-7330.32 K
Debt to Equity

0

Excellent
Altman Z Score

-9.37

Very Poor
Quick Ratio

0

Poor
Cash Ratio

8.59

Excellent


Highs/Lows of Dermata Therapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week3.38 13.46 % 0.513 % 3.923.2731-May-2428-May-24
Two Week4.2 8.69 % 0.486 % 5.03.2421-May-2422-May-24
One Month4.9065 21.84 % 4.80 % 6.1713.2410-May-2422-May-24
Three Month6.885 44.30 % 3.56 % 6.9363.2401-Mar-2422-May-24
Six Months11.181 65.70 % 15.54 % 13.21953.2405-Jan-2422-May-24
One year24.0 84.02 % 26.26 % 31.34853.2408-Jun-2322-May-24
Two year187.2 97.95 % 27.72 % 196.83.2426-Oct-2222-May-24
Five year12000.0 99.97 % 91.77 % 38.40.23222-May-2316-Apr-24


Technical View of Dermata Therapeutics Inc
RSI

41.43

Neutral
MACD

-0.487

Bearish
ADX

17.84

Neutral
Super Trend

5.20

Mild Bearish
Williams %R

-77.20

Mild Bullish
CCI

-60.69

Bullish


EMA 5

3.64

Strong Bullish
EMA 15

3.99

Mild Bearish
EMA 50

4.98

Mild Bearish
EMA 100

6.53

Strong Bearish
SMA 100

5.92

Strong Bearish
SMA 200

9.33

Strong Bearish
SMA 5 / 20

3.51 / 4.36

Mild Bearish
SMA 15 / 50

4.15 / 5.09

Strong Bearish
SMA 50 / 200

5.09 / 9.33

Mild Bearish




Charts of Dermata Therapeutics Inc


Returns of Dermata Therapeutics Inc with Peers
Period / StockDRMAPRFXQLGNBJDX
1 Week13.46%1.43%-11.48%8.16%
1 Mth-21.84%-23.12%-9.94%8.16%
3 Mth-44.30%-62.63%-41.32%-32.83%
6mth-65.70%-71.60%-61.98%-83.59%
1 Year-84.02%-84.57%-70.74%-88.79%
2 Year-97.95%-92.11%-95.19%-97.52%
5 Years-99.97%--99.88%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Dermata Therapeutics Inc with Peers
Ratio / StockDRMAPRFXQLGNBJDX
PE-0.121-0.077-0.076-0.065
P/B0.1610.1430.4030.175
ROA-112.87-139.60-156.96-179.39
ROE-132.91-186.67-709.27-273.28
Debt To Equity00.0077-0.6180.056
Revenue0
% 		0
100.00 % 		4983.56 K
0 % 		0
100.00 %
Net Income-7330.32 K
23.73 % 		-7619.00 K
13.34 % 		-17339.21 K
17.57 % 		-10037.40 K
7.96 %


Technicals of Dermata Therapeutics Inc with Peers
Technical / StockDRMAPRFXQLGNBJDX-
ADX17.8416.1013.8933.47
CMF-0.349-0.310-0.01660.094
MFI36.1046.5943.6642.73
RSI41.4332.7038.5747.14
MACD Abv SignalFalseTrueTrueTrue
Price Above 50 MAFalseFalseFalseFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : Dermata Therapeutics Inc

Address : 3525 Del Mar Heights Road, San Diego, CA, United States, 92130
Tel : 858 800 2543
URL : https://www.dermatarx.com
Code : DRMA, ISIN : US2498451085, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 13_Aug_2021
Employee Count : 8

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.


Note : All Data Generated at the End of Trading Hours (EOD Data)